Search results
Results from the WOW.Com Content Network
Genentech, Inc. is an American biotechnology corporation headquartered in South San Francisco, California, wholly owned by the Swiss multinational pharmaceutical company, the Roche Group. It became an independent subsidiary of Roche in 2009.
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Pages for logged out editors learn more
Efalizumab (brand name Raptiva, Genentech, Merck Serono) is a formerly available medication designed to treat autoimmune diseases, originally marketed to treat psoriasis.As implied by the suffix -zumab, it is a recombinant humanized monoclonal antibody administered once weekly by subcutaneous injection.
Genentech pioneered the use of recombinant human growth hormone for human therapy, which was approved by the FDA in 1985. [citation needed] Prior to its production by recombinant DNA technology, growth hormone used to treat deficiencies was extracted from the pituitary glands of cadavers. Attempts to create a wholly synthetic HGH failed.
By this method, body diagrams can be derived by pasting organs into one of the "plain" body images shown below. This method requires a graphics editor that can handle transparent images, in order to avoid white squares around the organs when pasting onto the body image. Pictures of organs are found on the project's main page. These were ...
Anatomography is an interactive website which supports generating anatomical diagrams and animations of the human body. The Anatomography website is maintained by the DBCLS (Database Center for Life Science) non-profit research institute located at the University of Tokyo.
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Pages for logged out editors learn more
It is marketed by both Abbvie and Genentech USA, which is a member of the Roche Group. [14] AbbVie and Genentech are both commercializing the drug within the United States, but only AbbVie has rights to do so outside of the U.S. [20] According to Reuters 2016 Drugs to Watch, the 2020 forecast sales for venetoclax are US$1.48 billion.